Brief Research Report ARTICLE
Changes in monoaminergic neurotransmission in an animal model of osteoarthritis: the role of endocannabinoid signaling
- 1Institute of Pharmacology, Polish Academy of Sciences, Poland
- 2Institute of Pharmacology, Polish Academy of Sciences, Poland
Chronic pain is a main symptom of osteoarthritis (OA). Moreover, a high percentage of OA patients suffer from mental health problems. The endocannabinoid (EC) system has attracted attention as an emerging drug target for pain treatment together with its activity on the mesolimbic reward system. Understanding the circuits that govern the reward of pain relief is crucial for the search for effective analgesics. Therefore, we investigated the role of the EC system on dopamine (DA) and noradrenaline (NA) in an animal model of OA-related chronic pain. OA rats exhibited significant decreases in DA metabolism in the nucleus accumbens (NAc), striatum (STR) and hippocampus (HC). NA metabolism was also significantly decreased by chronic pain in OA rats; however, this disruption was limited to the frontal cortex (FCx) and hippocampus (HC). URB597 (an inhibitor of endocannabinoid metabolism) treatment completely reversed the decreased dopamine metabolism, especially in the brain reward system and the HC. Furthermore, administration of URB597 normalized the impairment of NA activity in the HC but potentiated the decreased NA levels in the FCx. Our results demonstrated that chronic pain in OA rats was reflected by the inhibition of mesolimbic and mesocortical dopaminergic transmission, and may indicate the pro-pain role of NA in the FCx. The data provide understanding about changes in neurotransmission in chronic pain states and may explain the clinical improvement in perceived life quality following cannabinoid treatment. Additional mechanistic studies in preclinical models examining the intersection between chronic pain and reward circuits may offer new approaches for improving pain therapy.
Keywords: Osteoarthritis, Chronic Pain, catecholamines metabolism, brain structures, reward system, hypodopaminergia, endocannabinoid system
Received: 28 Sep 2018;
Accepted: 03 Dec 2018.
Edited by:Ildikó Rácz, Universitätsklinikum Bonn, Germany
Reviewed by:Livio Luongo, Università degli Studi della Campania "Luigi Vanvitelli" Naples, Italy
Bogna Ignatowska-Jankowska, Okinawa Institute of Science and Technology Graduate University, Japan
Copyright: © 2018 Mlost, Wąsik, Michaluk, Antkiewicz-Michaluk and Starowicz. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Dr. Katarzyna Starowicz, Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland, email@example.com